HOOK HOOKIPA Pharma Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
HB-101
Cytomegalovirus (CMV)
|
Phase 2
Phase 2
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
|
HB-201 and HB-202 (alone and double)
Treatment-refractory HPV16+ cancers
|
Phase 1/2
Phase 1/2
|
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
|
Latest News
-
View Full Article Hide Full Article
NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it will release financial results for the second quarter ended June 30, 2020 before the market opens on Thursday, August 13, 2020.
The Company will not be conducting a conference call in conjunction with this earnings release. Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body's immune system.
HOOKIPA's proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA's "off-the-shelf" viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA's non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.
Find out more about HOOKIPA online at www.hookipapharma.com.
HOOKIPA Forward Looking Statements
Certain statements set forth in this press release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA's ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA's ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA's quarterly report on Form 10-Q for the quarter ended March 31, 2020 which is available on the Security and Exchange Commission's website at www.sec.gov and HOOKIPA's website at www.hookipapharma.com.
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.
For further information, please contact:
Media
Nina Waibel
Senior Director - Communications
[email protected]Media enquiries
Instinctif Partners
[email protected]
+44 (0)20 7457 2020Investors
Matt Beck
Executive Director - Investor Relations
[email protected]
-
View Full Article Hide Full Article
NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, today announced that both the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued patents covering HOOKIPA's proprietary replicating arenavirus technology (TheraT®).
The patents (US Patent No. 10,722,564 and European Patent No. 3218504) are granted to the University of Geneva. HOOKIPA has exclusively licensed these patents from the University. The patent claims cover current product candidates based on HOOKIPA's replicating arenavirus platform technology (TheraT®), including the Company's lead oncology product candidates HB-201 and HB-202. These programs are currently in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers.
In addition to the replicating arenavirus platform patents, the USPTO recently granted a patent (US Patent No. 10,669,315) specifically related to HOOKIPA's HB-201 and HB-202 product candidates, which are two different replicating arenavirus-based vectors encoding the same E7/E6 fusion protein. The patent protection for HB-201 and HB-202 conferred by these platform and product-specific patents extends to 2037 in the United States and 2035 in Europe (not taking into account potential Patent Term Extension or Supplementary Protection Certificates).
"The newly issued patents provide general, long-term patent protection for our arenavirus technology and related oncology programs. The combination of broad patents on our arenavirus platform and specific patents on product candidates underpin the commercial potential of the therapies we are developing," said Joern Aldag, HOOKIPA's Chief Executive Officer.
About Replicating Arenavirus Technology (TheraT®)
HOOKIPA's proprietary and patented replicating arenavirus technology induces powerful immune responses. HOOKIPA's replicating arenavirus constructs are engineered to be specific for antigens of choice. Arenaviruses have a natural ability to evade neutralization, enabling repeated intravenous delivery.The replicating arenavirus platform is able to direct more than 50% of a mouse's T cells to focus on a single target of choice. In various animal models, immunization with HOOKIPA's replicating arenavirus resulted in elimination of a primary tumor and metastasis and provided long-term protection against a cancer re-challenge months after primary treatment. The Company believes that its arenavirus-based treatments are more potent immunotherapies than alternative therapeutic modalities.
HOOKIPA's lead oncology programs, HB-201 and HB-202 for the treatment of Human Papillomavirus 16-positive cancers, are both based on its replicating arenavirus platform.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body's immune system.HOOKIPA's proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA's "off-the-shelf" viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA's non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.
Find out more about HOOKIPA online at www.hookipapharma.com.
HOOKIPA Forward Looking Statements
Certain statements set forth in this press release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA's ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA's ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA's quarterly report on Form 10-Q for the quarter ended March 31, 2020 which is available on the Security and Exchange Commission's website at www.sec.gov and HOOKIPA's website at www.hookipapharma.com.
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.
For further information, please contact:
Media Investors Nina Waibel Matt Beck Senior Director - Communications Executive Director - Investor Relations [email protected] [email protected] Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020 -
View Full Article Hide Full Article
Genespire appoints Jörn Aldag as Chairman of the Board of Directors
Serial entrepreneur brings exceptional experience from a range of leadership rolesItaly, Milan, 30 July 2020: Genespire, a gene therapy company developing transformative therapies for genetic diseases, today announces the appointment of Jörn Aldag as Chairman of the Board.
Jörn Aldag brings 23 years of corporate and leadership experience in the life sciences industry from numerous, highly relevant roles, including as the CEO of gene therapy pioneer uniQure N.V. Since 2016 he is the CEO of HOOKIPA Pharma Inc. (NASDAQ:HOOK), a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancer based on its proprietary arenavirus platform. During his time at HOOKIPA, he has led the Company through significant growth, including the progression of several programs into clinical development, successfully completing numerous private financings, and a listing on NASDAQ in 2019, raising in total close to $200 million in proceeds. In addition to leading HOOKIPA, Jörn Aldag serves as a board member of Idorsia Pharmaceuticals Ltd, a biopharmaceutical company specialized in the discovery and development of small molecules to provide innovative therapeutic opportunities.
Prior to joining HOOKIPA, Jörn was CEO of uniQure N.V. (NASDAQ:QURE), where he led the company to obtaining the first regulatory approval of a gene therapy in Europe. Under his leadership, uniQure raised around $200 million in proceeds, and closed a multi-billion-dollar collaboration in cardiovascular gene therapy.
Previously, Jörn Aldag was President and CEO of Evotec AG, Chairman of the Board of Molecular Partners AG and co-founder of G7 Therapeutics AG, later sold to Heptares Therapeutics.
Commenting on his new appointment as Chairman of Genespire, Jörn Aldag said: "Gene therapy is coming of age. As Genespire's Chairman I will support Julia Berretta and her team in transforming two exceptional next generation gene therapy platforms into a pipeline of products. Genespire is built around novel gene editing and lenti-viral technologies, which we will use to develop life changing therapies to individuals affected by severe metabolic and immunodeficiency disorders."
Julia Berretta, Chief Executive Officer of Genespire, commented: "At Genespire we are committed to building an outstanding team. I am delighted to welcome Jörn Aldag to Genespire as Chairman. He brings a wealth of experience from across the life sciences sector which will be invaluable as we grow our team and drive the development of transformative therapeutic solutions for people suffering from genetic diseases."
Sofinnova Partners' Managing Partner, Graziano Seghezzi, added: "Jörn's stature and authority in the gene therapy domain is well known. He is one of the most accomplished entrepreneurs in the industry and has successfully mentored numerous high-performing biotech CEOs in achieving strategic and operational excellence. His appointment adds to the outstanding caliber of the
Genespire team and positions the company for continued success."In May, Genespire and SR-Tiget announced a strategic alliance for the development of transformative gene therapies for genetic diseases (the full press release can be accessed here).
Most recently, in June, Genespire and the San Raffaele Telethon Institute for Gene Therapy announced publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells (the full press release can be accessed here).
-ends-
Enquiries:
Genespire Tel: +39 02 83991300
[email protected]Consilium Strategic Communications Tel: +44 (0) 20 3709 5700 Amber Fennell / Ashley Tapp [email protected] About Genespire
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini and Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. Genespire is a spin-out of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. Find out more about us at www.genespire.com.
-
View Full Article Hide Full Article
- Interim data demonstrate that HB‑101 is well tolerated
- HB-101 elicits T cell and B cell responses in the target population
NEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced positive interim results on its prophylactic Cytomegalovirus (CMV) vaccine candidate HB‑101. HB‑101 is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in patients receiving a kidney transplant from a live donor. HOOKIPA reported interim data on the trial's primary endpoints, safety and B cell and T cell immunogenicity.
Trial participants were blinded and randomized 2:1 to receive either HB‑101 or placebo. Patients received either 2 or 3 doses prior to transplantation, depending on the transplantation time schedule.
Tolerability profile of HB‑101
Safety and tolerability were evaluated in 51 CMV-negative patients prior to kidney transplantation. Of the 51 patients, only eight patients (16%) across the combined, blinded HB-101 and placebo groups showed adverse events related to the administration. Most of these adverse events were of mild intensity, indicating that HB‑101 is generally well tolerated in this patient population. Of note, this target patient population reported fewer adverse events than the 54 healthy volunteers in HOOKIPA's recently published Phase 1 trial results1.CMV-neutralizing antibody response to HB‑101
For the interim analysis, CMV-neutralizing antibody titers on the day of transplantation were evaluated in all of the 30 CMV-negative patients who had been transplanted by the cutoff date and had valid results. Nineteen of the 30 patients received HB-101 and eleven received placebo. All five patients (100%) who received three doses of HB‑101 mounted CMV-neutralizing antibodies. Three of the fourteen patients (21%) who received only two doses of HB‑101 also mounted CMV-neutralizing antibodies. The antibody response of the kidney transplant recipients who completed the three-dose regimen was comparable to the antibody response observed in the Phase 1 trial.T cell responses to HB-101
Cellular immune responses to CMV on the day of transplantation were evaluated in 25 CMV-negative patients who had been transplanted in time for this interim analysis. Technically valid results from T cell assays on the day of transplantation were available for seven recipients (as a consequence of sample logistics and assay performance). Two of the seven patients received placebo and five received HB‑101. All three patients (100%) who received three doses of HB‑101 and one of the two patients who received only two doses (50%) mounted a CMV-specific cellular immune response.Conclusions:
The interim data demonstrate that HB‑101 is well tolerated with fewer adverse events in patients with end-stage kidney disease than in the previous healthy volunteer trial. Patients who received three doses of HB‑101 show comparable immunogenicity to healthy volunteers in HOOKIPA's Phase 1 clinical trial of HB‑101."The interim results demonstrate that the vaccine is well-tolerated and immunogenic in patients with end-stage kidney disease," said Joern Aldag, CEO. "We are excited that we are seeing strong antibody and T cell responses, in particular in patients who received three administrations. We continue patient accrual and plan to report preliminary efficacy data and updated safety and immunogenicity data by the end of 2020."
About Cytomegalovirus
Cytomegalovirus, or CMV, is a virus that is commonly transmitted in childhood and early adulthood. Approximately 60% of the U.S. population has been exposed and is latently infected. Worldwide data indicate that half the people in industrialized countries and up to 99% of people in developing countries, including China and India, have been infected. Infections typically result in lifelong latent persistence of the virus with few symptoms, if any. However, in unborn children, when infected in utero, CMV infection can lead to significant morbidity and mortality. In addition, in immunosuppressed patients, such as transplant recipients, primary CMV infection or reactivation of CMV causes significant morbidity, mortality and graft rejection.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.
HOOKIPA's proprietary arenavirus-based technologies, VaxWave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA's VaxWave®-based prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors as well as CMV-positive patients awaiting kidney transplantation from CMV-positive or -negative donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT® based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.
Find out more about HOOKIPA online at www.hookipapharma.com.
HOOKIPA Forward Looking Statements
Certain statements set forth in this press release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA's ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA's ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA's quarterly report on Form 10-Q for the quarter ended March 31, 2020 which is available on the Security and Exchange Commission's website at www.sec.gov and HOOKIPA's website at www.hookipapharma.com.
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.
For further information, please contact:
Media Investors Nina Waibel Matt Beck Senior Director - Communications Executive Director - Investor Relations [email protected] [email protected] Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020 ________________
1 Schwendinger M, et al. J Infect Dis. 2020. pii: jiaa121. doi: 10.1093/infdis/jiaa121
- Interim data demonstrate that HB‑101 is well tolerated
-
View Full Article Hide Full Article
NEW YORK and VIENNA, Austria, June 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that Dr. Sander van Deventer has resigned as a Non-Executive Director of the Company's Board of Directors and Audit Committee.
Sander van Deventer, who joined the Board of Directors in 2011, will continue to serve as a member of HOOKIPA's Scientific Advisory & Review Committee.
Dr. Jan van de Winkel, Chairman of the Board of Directors at HOOKIPA, said: "On behalf of my fellow Board members and HOOKIPA's executive team, I would like to thank Sander for his major contributions to building our company. His extensive experience and creative insights played an important part in our development and he leaves with our very best wishes for the future."
HOOKIPA's Board of Directors will now consist of 8 members, including Dr. Jan van de Winkel as Chairman, Michael A. Kelly, Dr. David R. Kaufman, Dr. Christoph Lengauer, Julie O'Neill, Graziano Seghezzi, Joern Aldag, and Reinhard Kandera.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.HOOKIPA's proprietary arenavirus-based technologies, VaxWave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA's VaxWave®-based prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors as well as CMV-positive patients awaiting kidney transplantation from CMV-positive or -negative donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and chronic Hepatitis B infections.
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT® based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact: Media Investors Nina Waibel Matt Beck Senior Director - Communications Executive Director - Investor Relations [email protected] [email protected] Media enquiries Instinctif Partners [email protected] +44 (0)20 7457 2020